I have two biomarkers that I plan to be observed in my intervention study. One is the changes of circulating levels of dihomo-γ-linolenic acid (C20:3n-6, DGLA), and another one is Δ-5 desaturase (D5D, an enzyme catalyzing the conversion of dihomo-γ-linolenic acid to arachidonic acid) activity.
I searched literature and found that, compared with the control group, significantly higher circulating levels of DGLA and lower D5D activity were observed in the liver steatosis and obese group, respectively.
If the intervention study has favorable metabolic results, what should I expect to see in the changes of these two biomarkers? Will decreased DGLA levels and increased D5D activity be a positive intervention results?